RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome (Q24623137)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome	scientific article

Statements

scholarly article

0 references

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome (English)

0 references

0 references

placebo-controlled trial

1 reference

based on heuristic

inferred from title

acute coronary syndrome

1 reference

based on heuristic

inferred from title

4

object named as

Gregory Y H Lip

0 references

Christopher B. Granger

10

object named as

Christopher B Granger

0 references

J Wouter Jukema

3

object named as

J Wouter Jukema

0 references

author name string

Ph Gabriel Steg

1

0 references

Shamir R Mehta

2

0 references

C Michael Gibson

5

0 references

Frantisek Kovar

6

0 references

Petr Kala

7

0 references

Alberto Garcia-Hernandez

8

0 references

Ronny W Renfurm

9

0 references

language of work or name

0 references

publication date

October 2011

0 references

European Heart Journal

0 references

32

0 references

20

0 references

2541-54

0 references

Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Warfarin, aspirin, or both after myocardial infarction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Ticagrelor versus clopidogrel in patients with acute coronary syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

7 April 2017

Apixaban with antiplatelet therapy after acute coronary syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

Clinical pharmacology of direct and indirect factor Xa inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

Clinical end points in coronary stent trials: a case for standardized definitions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the M

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology Task Force on Clinical Data Standards (Acut

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

Oral anticoagulant drugs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

27 September 2017

Predictors of hospital mortality in the global registry of acute coronary events

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3295208

30 May 2018

Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial.

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2).

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

Prasugrel versus clopidogrel in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

A Replacement for Warfarin

1 reference

https://api.crossref.org/works/10.1093%2FEURHEARTJ%2FEHR334

21 January 2018

2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, pla

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/21878434

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1093/EURHEARTJ/EHR334

0 references

0 references

0 references

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24623137&oldid=1950337416"